Explore the words cloud of the PROVEC project. It provides you a very rough idea of what is the project "PROVEC" about.
The following table provides information about the project.
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
|Coordinator Country||Germany [DE]|
|Total cost||2˙205˙875 €|
|EC max contribution||2˙205˙875 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2019-02-01 to 2024-01-31|
Take a look of project's partnership.
|1||MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV||DE (MUENCHEN)||coordinator||2˙205˙875.00|
The skeletal system and its vasculature form a functional unit with great relevance in health, regeneration, and disease. Our recent work has provided fundamental insights into the organization of the bone vasculature in mouse, its changes during aging, the heterogeneity and functional specialization of bone capillaries and endothelial cells, the regulation of these properties by Notch and hypoxia-inducible factor signaling, and the crosstalk with osteoblast lineage cells. Most importantly, we found that the manipulation of ECs in the aging animal can trigger the expansion of osteoprogenitors and thereby induce bone formation. PROVEC will now systemically identify and characterize endothelial cell subpopulations, their gene expression and functional properties in the healthy, aging, diseased and regenerating skeletal system. Preclinical models will establish whether endothelial cells are involved in the response to therapeutic treatments aiming at osteoblasts or osteoclasts, or if the modulation of ECs alone is sufficient to generate beneficial effects. Finally, PROVEC will investigate whether cultured mouse and human ECs can be endowed with beneficial properties to enhance bone formation in 3D organoid cultures and after transplantation into mice, which will be monitored by imaging in living animals. To achieve its ambitions aims, PROVEC will use a powerful combination of mouse genetics, disease models, genetic fate mapping, RNA-seq and single cell sequencing, computational biology, confocal and 2-photon microscopy, micro-CT imaging, pharmacological treatments, and cell biology methods to establish if and how vascular endothelial cells can be used to increase bone mineral density in preclinical models. The successful completion of PROVEC would be highly relevant for diseases such as osteoporosis, which affects around 27.5 million patients in the EU, generates annual costs of about 37 billion Euros, and for which we currently lack appropriate treatments.
|year||authors and title||journal||last update|
Kishor K Sivaraj, Backialakshmi Dharmalingam, Vishal Mohanakrishnan, Hyun-Woo Jeong, Katsuhiro Kato, Silke SchrÃ¶der, Susanne Adams, Gou Young Koh, Ralf H Adams
YAP1 and TAZ negatively control bone angiogenesis by limiting hypoxia-inducible factor signaling in endothelial cells
published pages: , ISSN: 2050-084X, DOI: 10.7554/elife.50770
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROVEC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PROVEC" are provided by the European Opendata Portal: CORDIS opendata.